融合素的候选先导药物是西夫韦肽，一种HIV融合抑制剂。
The lead drug candidate in FusoGen's pipeline is Sifuvirtide, an HIV fusion inhibitor.
因此以经典肽为活性先导化合物进行结构改造成为开发新药的理想途径之一。
Therefore, structure modification of classical peptide becomes a preferable way for drug research and development.
结论：化学合成的小肽p5有望作为先导分子，在以KDR为靶点的肿瘤靶向治疗中得到应用。
Conclusion: the peptide P5 that home to KDR expressed on tumor vasculature may also be useful in targeting therapies specifically to tumors.
结论：化学合成的小肽p5有望作为先导分子，在以KDR为靶点的肿瘤靶向治疗中得到应用。
Conclusion: the peptide P5 that home to KDR expressed on tumor vasculature may also be useful in targeting therapies specifically to tumors.
应用推荐